ArticleBMC infectious diseases2025
Identification of enterovirus 71 hand, foot and mouth disease from other enteroviruses by microfluidic digital PCR.
Article in BMC infectious diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Enterovirus71 (EV71) is a major etiological agent of severe hand, foot, and mouth disease (HFMD), which can lead to central nervous system damage in children. Reverse transcription quantitative polymerase chain reaction (RT-qPCR) often produces false-negative results during the early stage of EV71 infection, attributable to the low viral load. To address this limitation, we developed a rapid, precise, and highly sensitive multiplex reverse transcription digital polymerase chain reaction (RT-dPCR) assay for differential diagnosis of EV71-induced HFMD and non-EV71 pathogens. The EV71 RT-dPCR assay targeted the viral structural protein VP2 using a TaqMan minor groove binder (MGB) probe. This method achieved a detection sensitivity of 7.406 copies per microliter. Specificity analysis confirmed no cross-reactivity with non-EV71 enteroviruses. When validated against 60 clinical samples, the assay demonstrated 100% overall agreement (60/60) with a kappa value of 1.0 (p < 0.001). The developed EV71 RT-dPCR assay may facilitate early diagnosis of severe EV71-associated HFMD, enabling timely intervention for affected children.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.